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Abstract 
 
Alzheimer’s disease (AD) is most common form of dementia. Symptomatically, memory loss and 
cognitive decline is observed. In 2016, more than 33 million people worldwide are suffered from AD. 
The complexity of AD, however, stems from the inter-relation of multiple pathological factors upon 
initiation and progression of the disease. For example, the amyloid- (A) peptides aggregate toward 
bigger species and form the senile plaque in AD brain. The high concentration of metal ions [e.g., 
Cu(I/II), Zn(II), and Fe(II/III)] are observed in this senile plaques. Metal ions also could bind to A 
and show different properties with metal-free A. Additionally, from these redox active metal ions 
[e.g., Cu(I/II) and Fe(II/III)], could overproduce the reactive oxygen species (ROS) through Fenton-
like reactions. To identify the involvement of metal-bound amyloid- (metal–A) aggregation in AD 
pathology, small molecules as chemical tools capable of controlling metal–A aggregation have been 
developed. Herein, we describe the design of small molecules as chemical tools to target metal–A. 
Introduction of hypotheses of the AD and previous reported chemical tools for metal–A in Chapter 1, 
and 2,2’-bipyridine (bpy) derivatives (1–4) rationally designed to be chemical modulators towards 
metal–A aggregation over metal-free A analog will be described in Chapter 2. Additionally, design 
molecule to inhibit the transcription factor, FosB are proposed in Appendix A. Overall, our studies of 
the bpy derivatives demonstrate that the alteration of metal binding properties as well as the 
installation of an A interacting capability onto a metal chelating framework, devised via the rational 
structure-based design, were able to achieve evident modulating reactivity against metal–A 
aggregation. Obviating the need for complicated structures, our design approach could be 
appropriately utilized for inventing small molecules as chemical tools for studying desired metal-
related targets in biological systems. 
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Pathological Features in Alzheimer’s Disease and  
Chemical Tools to Understand Their Complexity 
 


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1.1 Introduction 
Alzheimer’s disease (AD), mortal neurodegenerative disease, is the most common form of dementia.1 
In 2016, over 33 million people worldwide were represented to be suffered from AD.1 The number of 
patients is predicted to be about 131 million by 2050.1 In AD brain, senile plaques (SPs) and 
neurofibrillary tangles (NFTs) which are composed by amyloid- (A) and phosphorylated tau (ptau) 
respectively, are considered as a hallmark of AD.2-7 Including these hallmark, multiple pathological 
features (i.e., A aggregation, dishomeostesis and miscompartmentalization of metal ions, and 
oxidative stress) have been suggested to be independently or simultaneously affected in AD, causing 
the complexity of AD, the obstacle of illuminating its elemental cure of disease.2,3,8-10 
The A could aggregate themselves and form the SPs, the hallmark of AD.9,11 In this senile 
plaques, metal ions [i.e., Cu(I/II), Zn(II), and Fe(II/III)] is observed to be higher concentration than 
normal brain.2,10,12-16 From redox-active metal ions [i.e., Cu(I/II) and Fe(II/III)], reactive oxygen 
species (ROS) could be over produced by Fenton-like reaction.2,10,12-15 Herein, we would be focusing 
on three hypothesis (e.g., amyloid cascade hypothesis, metal ion hypothesis, and oxidative stress 
hypothesis) and their relationship and chemical tools to study them are described. 
 
1.2 Alzheimer’s Disease (AD) 
1.2.1 Amyloid Cascade Hypothesis 
The A peptide is produced by proteolytic cleavage of the amyloid precursor protein (APP).10,17 The 
- and -secretases cleavage the transmembrane portion of the APP, and generate mainly two isoforms, 
A40 and A42.2,3,8 The A42 have only two additional hydrophobic C-terminal residues (I41 and A42) 
which direct the peptide more aggregation; thus, A42 is considered more pathogenic than A40.2-5,8  
After proteolytic cleavage, A monomers interact with another monomer through their self-
recognition site and initiate aggregation to larger species toward oligomers or fibrils.2,3,8,9 Recently, 
among of these conformations, soluble A oligomer is suggested more neurotoxic than other A 
species through disrupting cellular membranes and signaling.9,11  
 
1.2.2 Metal Ion Hypothesis 
Homeostasis of metal ions is highly regulated in living organisms.2,18 Cu and Zn are represented to be 
involved in neuronal transmission in the brain.2,18-21 Therefore, broken of balance of metal ions can be 
a resulting in disease or death through initiate or develop the pathological pathway.2,18 In the AD brain, 
SPs and NFTs are appeared with miscompartmentalization and dishomeostasis of metal ions.2,6,22 In 
SPs of AD brain, highly concentration of Cu (ca. 0.4 mM), Zn (ca. 1 mM), and Fe (ca. 0.9 mM) have 
been detected.2,6,13  
These high concentration of metal ions [i.e. Cu(I/II) and Zn(II)] could directly bind with A and 
㸱 
 
forming the metal-associated A (metal–A) were observed.2,10,12-15,23-25 Binding of Cu(II) to A 
suggested to prefer a square planar geometry showing two coordination modes (component I and II) 
that are dependent on pH; Component I for pH 6.5 and Component II for pH 9).6,14-16 In component I, 
Cu(II) is surrounded by a nitrogen (N) donor atom from N terminus, two N donor atoms from His 
residues (H6, and H13 or H14), and one oxygen (O) donor atom from backbone carbonyl group of D2 
(3N1O).2,6,13-15 Component II have 3N1O binding environment with one N donor atom from His 
residue (H6, H13, or H14), two N donor atom from N-terminus amine group and peptide backbone 
amine group of D1-A2, and one O donor atom from carbonyl group of A2-E3.2,6,13-15 Zn(II) binding 
with A is also expected to coordinate with four to six ligands; three His residues, an addition O 
donor atoms (D1, R5, Y10 or E11) and exogenous water molecule.2,6,13-15 
 
1.2.3 Oxidative Stress Hypothesis 
Redox active metal ions [e.g., Cu(I/II) and Fe(II/III)] associated with A are involved in Fenton-like 
reactions.2,26 They are suggested to be implicated in producing pathway of the ROS [e.g., Hydrogen 
peroxide (H2O2) and superoxide (O2-)] leading to oxidative stress. 2,4,26,27 When O2- are produced too 
much to scavenged by superoxide dismutase, it could react with nitric oxide (NO) and form the 
peroxynitrite (ONO2-), which can oxidize the lipid, protein, and DNA.3 Additionally, H2O2, strong 
oxidant, can react with organic molecules and form the peroxy adducts which could be implicated 
upregulate stress-activated protein kinases.3 
 
1.3 Metal-bound A and Chemical Tools in AD 
1.3.1 Metal-bound A  
The metal ions [e.g., Cu(II) and Zn(II)] associated A are more facilitated aggregation pathway than 
metal-free A and stabilize toxic soluble A oligomer form.2,13-16 Also, through the Fenton-like 
reaction, ROS could be overproduced in the brain.2,10,12-15 For more understanding of metal–A in AD, 
small molecule as a chemical tool was adopted to target and control the pathological pathway of 
metal–A. 
 
1.3.2 Design of Chemical Tools for Metal–A 
The small molecules for targeting the metal–A, should have A interaction moiety and metal binding 
site in the molecule.5,25,28 For example, the dimethyl amino group is already known to be important in 
A interaction when it is attached on the aromatic rings.9,23,25,29-31 Furthermore, metal binding affinity 
of molecule is not in the appropriate range (ca. Kd ~ 10-12–10-9 for Cu(II)–A, Kd ~ 10-9–10-6 for 
Zn(II)–A), molecule could not interact with A or just chelating out the metal ions from metal–
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A.2,10 Additionally, for targeting the metal–A in the brain, the molecules are preferred to be 
permeable toward blood-brain barrier (BBB) and water soluble.25,32-34 The chemical tools to target 
metal–A considered their A interaction, metal binding and BBB permeability are determined their 
reactivity by in vitro assays. 
 
 
 
Figure 1.1. Library of chemical tools for targeting Metal–A. (a) rationally designed small molecules  
(b) structure modified molecules from L2-b. 
 
Following the incorporation design approach, the A imaging agent, stilbene derivative was 
incorporated with metal binding donor atom.5,25,28 The designed molecule (L2-b) have reactivity 
toward Cu(II)–A and Zn(II)–A; modulate the aggregation pathway of metal–A over metal-free 
A.25 Furthermore, the structure of L2-b was employed to study the structure-activity relationship 
through the simple structure modification.32 The simply modified molecule could target different 
pathological factors.32 The modified molecules (1–4) could have different pathological factors for 
their target: 1 and 2 could target Cu(II)–A; 3 could target both Cu(II)–A and Zn (II)–A; 4 could 
target all of metal-free A, Cu(II)–A and Zn (II)–A. 32 
In contrast with L2-b, the molecules were designed from the metal chelator framework [e.g., 
2,2’-bipyridine (bpy)].33 For interaction with A, dimethyl amino group, which known as A 
interaction moiety was incorporated on bpy backbone.9,23,25,29-31 Also metal binding affinity was 
slightly modified by differently positioned methyl group.33 These molecule also could modulate 
metal–A aggregation pathway in vitro.33 
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In different design approach, coordination geometry (e.g., square planar) of Cu(II) with ligand 
was fixed by molecular structure and prevented the reducing of Cu(II).34 The designed molecule have 
3N1O coordination environment with 8-hydroxyquinoline derivative.34 Because of structure of 
molecule (ML), coordination with Cu(II) form the tilted square planar was designed which have tilted 
square planar when they bind with Cu(II).34 Additionally, for A interacting moiety was adopted to be 
reactive with A.34 Actually, ML could also modulate aggregation pathway of metal–A, and 
suggested to decrease Cu(II) reducing toward Cu(I) by coordination geometry.34 
The reactive molecules with metal–A are investigated their neurotoxicity in the cell before in 
vivo experiments. From these studies, the knowledge of chemical tool design strategy and their 
reactivity could be valuable for another chemical tool or drug development. 
 
1.4 Conclusions 
AD is a critical disease for human being and more crucial in the future. Its complexity from multiple 
and inter-related pathological factors making the elucidation of etiology difficult. Currently the 
amyloid cascade hypothesis suggests that A aggregates are involved in pathological pathway of AD. 
Additionally, metal ion dishomeostasis and miscompartmentalization is observed of another hallmark 
of AD. The metal ions [e.g., Cu(II) and Zn(II)] binding A and form metal–A, facilitate the 
aggregation pathway, stabilize toxic oligomer form, and overproduce ROS resulting in oxidative 
stress. For better understanding of the role of metal–A in AD, small molecules have developed as 
chemical tools to target metal–A and modulate their pathological pathway. Several compounds with 
various frameworks have been employed to investigate the metal–A interaction, and this study will 
be valuable to elucidate the unclear involvement of metal–A in AD. Furthermore, the 
pharmacological properties of molecules will be helpful for designing different chemical tools or drug. 
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2.1. Introduction 
In 2016, over 47 million people worldwide were reported to be affected by dementia.1 This number is 
speculated to reach about 131 million by 2050.1 Alzheimer’s disease (AD) is the most common form 
of dementia, representing 60 to 80% of cases.1 Multiple pathological features [e.g., amyloid- (A) 
aggregation, metal ions dyshomeostasis and miscompartmentalization, oxidative stress] have been 
observed to be individually or mutually involved in AD development, indicating the difficulty of 
elucidating its etiology.2-8 A peptides, one of the pathological factors, are denoted for their ability to 
self-aggregate and exist in various conformations, including monomers, oligomers, and fibrils.2-5 
Recently, among these conformations, A oligomers have been suggested to be the toxic species able 
to damage cells through disrupting cellular membranes and signaling.5,9 In addition, through the 
interaction between A and membranes, A aggregation is suggested to be facilitated resulting in the 
enhancement of its toxicity.9 Moreover, abnormally high concentrations of metal ions [ca. 400 M for 
copper and ca. 1 mM for zinc] are found from A aggregates in the AD-affected brain.4,6-8,10-16 These 
metal ions [i.e., Cu(II) and Zn(II)] are reported to directly bind to A, facilitate its aggregation, and 
promote the generation and stabilization of A oligomers, suggested to be toxic.4,6-8,10-16 Thus, metal-
bound A (metal–A) complexes have been proposed to be linked to AD pathogenesis through direct 
interactions between metal ions and A.4,6-8,10-16 
To identify the relationship between metal–A aggregation and neurotoxicity found in AD at the 
molecular level, chemical tools able to control the aggregation of metal–A have been recently 
developed by rational structure-based design strategies.7,12,17-28 Among them, some examples of small 
molecules have been constructed through the incorporation approach (i.e., introduction of structural 
moieties critical for the desired properties, including metal binding and A interaction, in a single 
molecular entity).17,19,21,24,25,27,28 This design strategy has been producing such chemical tools with 
relatively small sizes [e.g., molecular weight (MW) less than approximately 400 g/mol], giving them 
the advantage of being potentially available in the brain.17 A recent study presented the smallest 
blood-brain barrier (BBB)-permeable chemical reagent, DMPD (MW = 136 g/mol), capable of 
interacting and reacting with both metal-free A and metal–A.25 
Herein, we report a new class of compact 2,2’-bipyridine (bpy) derivatives (1–4; Figure 2.1) 
rationally designed to modulate the aggregation of metal–A over metal-free A. The bidentate ligand, 
bpy (structure shown in Figure 2.1), is commonly used as a metal chelator for various metal ions, 
including Cu(II) and Zn(II).29-32 Until now, to the best of our knowledge, the bpy ligand itself as well 
as its derivatives have not been studied as potential chemical tools capable of interacting with 
complexes of metal–A and altering their aggregation pathways. In order to control metal–A 
aggregation, the essential properties of A interaction and appropriate metal binding were instilled 
onto the bpy framework through two straightforward structural variations (Figure 2.1): (i) 
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incorporation of a reported A targeting moiety, the dimethylamino functionality;17,27,33-35 (ii) 
modification of metal binding affinities and/or steric hindrance at the metal chelation site via 
differently positioning an electron-donating methyl group36 on the structure of bpy, along with a 
dimethylamino moiety,36 thus changing the structural and electronic characteristics for metal binding. 
Our in vitro investigations, including metal binding, metal–A interaction, and effects on metal-free 
A and metal–A aggregation, of the new bpy derivatives demonstrate that rational, straightforward 
structural variations on a simple metal chelator could construct novel chemical tools that can interact 
with metal–A over metal-free A, subsequently regulating metal–A aggregation. Moreover, our 
structure-based design of compact compounds as modulators against metal–A aggregation, presented 
in this work, could be further utilized to develop chemical tools for investigating metal–amyloid 
species found in amyloid-related disorders. 
 
 
 
Figure 2.1. Rational structure-based design of chemical tools able to interact and react with metal–A 
employing the framework of 2,2’-bipyridine (bpy). An A interacting moiety (i.e., dimethylamino 
functionality), along with a methyl group at different positions from the metal chelation site, was 
incorporated onto the bpy backbone. The N donor atoms for metal binding are highlighted in blue. 
 
2.2. Results and Discussion 
2.2.1. Design Rationale and Preparation of bpyGDerivatives.  
Through the incorporation approach, a new class of small molecules (bpy derivatives; Figure 2.1) was 
designed by installing a dimethylamino group (for Ainteraction and electronic influence on metal 
binding)17,27,33-36 as well as a methyl group (for electron donation and/or steric hindrance)30,36,37onto 
the bpy framework. A well-known metal chelator, bpy (Figure 2.1), was selected as the main 
structural backbone based on multiple characteristics: (i) the capability of binding to metal ions 
through two nitrogen (N) donor atoms [particularly, Cu(II) and Zn(II); formation constant values 
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(logkf) of Cu(II)–bpy and Zn(II)–bpy have been reported to be ca. 7.0 and ca. 6.0, respectively]29-32; 
(ii) relatively good solubility in aqueous media (e.g., 5.9 mg/mL in water)38; (iii) potential 
applications in the brain (e.g., intraperitoneally administered bpy was able to prevent and reduce 
intracerebral hemorrhage in vivo)39; (iv) ease of structural transformations.40 In addition, previous 
studies of bpy reported its ability to regulate metal-mediated reactions in biological systems [e.g., 
reducing the formation of hydrogen peroxide triggered by Fe(II/III)],41,42 supporting its applicability in 
biology.  
The new bpy derivatives (1–4; Figure 2.1) were fashioned to change their binding affinities to 
Cu(II) and Zn(II). Such variation in the metal binding affinities of the bpy derivatives was achieved 
by introducing a dimethylamino group on one pyridine ring as well as a methyl group as an electron-
donating group36 at ortho, meta, and para positions to the N atom on the other pyridine ring. In 
addition to the electronic aspect, the incorporation of a methyl group at the ortho position to the N 
donor atom of the pyridine ring (4, Figure 2.1) was expected to exhibit steric hindrance at the metal 
chelation site, as previously presented.30,37 Moreover, to introduce A interaction onto the backbone of 
bpy, the dimethylamino functionality, suggested to be an A interacting portion,17,27,33-35 was located 
at the para position to the N donor atom of one pyridine ring where the steric interference between its 
metal chelation site and the A interacting group could be minimized (see 1–4). 
 
Scheme 2.1. Synthetic routes to 1–4.G
G G
Reagents and conditions: (i) n-BuLi, 2-dimethylaminoethanol, hexanes, 0 °C; Bu3SnCl, –78 °C, yield: 
78%; (ii) PdCl2(PPh3)2, LiCl, PPh3, toluene, 110 °C, yield (for 1–4): 33-50%.G
 
The new bpy derivatives (1–4) were synthesized as depicted in Scheme 1. The precursor, N,N-
dimethyl-2-(tributylstannyl)pyridin-4-amine, was produced by stannylation of lithiated 4-
dimethylaminopyridine with tributyltin chloride. The bpy derivatives were prepared by a Stille cross-
coupling reaction,43,44 in which N,N-dimethyl-2-(tributyl-stannyl)pyridin-4-amine was allowed to 
react with the appropriate aryl bromides (2-bromopyridine or 2-bromo-n-methylpyridine, n = 4-6) 
using the palladium catalyst, PdCl2(PPh3)2 (5 mol%), and triphenylphosphine. All bpy derivatives 
were obtained through purification by column chromatography in modest yields (ca. 33-50%). 
 
2.2.2. Metal Binding Properties of bpy Derivatives.  
First, metal binding of the newly prepared bpy derivatives (1–4; Figure 2.1) was monitored by UV–
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visible spectroscopy (UV−vis) (Figure 2.2). The bpy ligand showed spectral changes upon addition of 
Cu(II) and Zn(II), consistent with previously reported data.31,32 Two noticeable alterations in the 
UV−vis spectra of the bpy derivatives in the presence of CuCl2 were observed (Figure 2.2a): (i) 
hyperchromic shifts at ca. 300/310 nm (for bpy) or ca. 340 nm (for 1–4); (ii) bathochromic shifts of 
the overall spectra. The samples coincubated with the bpy derivatives and ZnCl2 exhibited similar 
optical changes to those treated with CuCl2 with the exception of 4 (Figure 2.2b), displaying 
hyperchromic shifts of the peaks at ca. 295/306 nm (for bpy) or ca. 248/282 nm (for 1–4) 
accompanied by a relatively less significant bathochromic shift of the overall spectra. Binding of the 
bpy derivatives with Cu(II) or Zn(II) was evidenced by these optical deviations. 
 
 
Figure 2.2. Cu(II) and Zn(II) binding of bpy and 1–4. UV−vis spectra of ligands (black lines) upon 
addition of Cu(II) or Zn(II) (from 0.5 to 5 equiv). Conditions: [compound] = 50 M [for bpy and 1–3; 
[4] = 50 M (for Cu(II) binding) and 100 M (for Zn(II) binding)]; [CuCl2 or ZnCl2] = 0, 25, 50, 100, 
and 250 M (for 1–3; for 4, [CuCl2] = 0, 25, 50, 100, and 250 M, [ZnCl2] = 0, 50, 100, 200, and 500 
M); pH 7.4; 10 min; room temperature. 
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Figure 2.3. Solution speciation studies of bpy and 1–4. UV−vis variable-pH titration spectra (left) 
and solution speciation diagrams (right) of (a) bpy, (b) 1, (c) 2, (d) 3, and (e) 4 (FL = fraction of 
species at given pH). Acidity constants (pKas) of L (L = bpy and 1–4) are summarized in the table 
(bottom). Conditions: [L] = 25 M; room temperature. Charges are omitted for clarity. aThe error in 
the last digit is shown in the parentheses. 
 
Second, UV−vis variable-pH titration experiments were conducted to determine the solution 
speciation of the bpy derivatives in the absence and presence of Cu(II) or Zn(II) (Figure 2.3, 2.4, and 
2.5). Based on the titration results of bpy and 1–4, the solution speciation diagrams were depicted in 
Figure 2.3. The diagrams (i) revealed that two solution species of bpy and 1–4 [i.e., neutral (L) and 
monoprotonated (LH) forms (protonated at the N atom on the pyridine ring with the dimethylamino 
functionality)] existed in the pH range of ca. 3.5-6 for bpy and ca. 6-10 for 1–4; (ii) predicted L and 
LH to be the predominant species for bpy and 1–4, respectively, at a physiological pH (i.e., 7.4); (iii) 
determined the acidity constants (pKas) of the ligands [for bpy, pKa = 4.46(0); for 1, pKa = 8.47(8); for 
2, pKa = 8.59(3); for 3, pKa = 8.66(6); for 4, pKa = 8.67(4)]. The electron density of the N atom was 
enhanced from the electron donation of the dimethylamino group,36 incorporated at the para position 
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to N donor atom of one pyridine ring, resulting in the elevation of the bpy derivatives’ pKa values. 
Protonation at the N atom of 1–4 was estimated to be relatively easier than that of bpy. Thus, the 
structural variation which could lead to the modified pKa values of the N donor atom(s), responsible 
for metal binding, could alter metal binding affinities of molecules and subsequently direct their 
ability to modulate metal–A aggregation (vide infra). Additionally, the introduction of a methyl 
group on the bpy framework also raised the pKa. 
 
 
Figure 2.4. Solution speciation studies of Cu(II)–L complexes (L = bpy and 1–4). UV−vis variable-
pH titration spectra (left) and solution speciation diagrams (right) of (a) bpy, (b) 1, (c) 2, (d) 3, and (e) 
4 upon incubation with Cu(II) (FCu = fraction of species at given pH). Stability constants (log) of 
Cu(II)–L complexes are summarized in the table (bottom). Charges are omitted for clarity. Conditions: 
[L] = 25 M; [CuCl2] = 12.5 M; room temperature. aThe error in the last digit is shown in the 
parentheses. 
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Figure 2.5. Solution speciation studies of Zn(II)–L complexes (L = bpy and 1–4). UV–vis variable-
pH titration spectra (left) and solution speciation diagrams (right) of (a) bpy, (b) 1, (c) 2, (d) 3, and (e) 
4 upon incubation with Zn(II) (FZn = fraction of species at given pH). Stability constants (log) of 
Zn(II)–L complexes are summarized in the table (bottom). Charges are omitted for clarity. Conditions: 
[L] = 25 M (for bpy and 1–3) or 100 M (for 4); [ZnCl2] = 12.5 M (for bpy and 1–3) or 50 M 
(for 4); room temperature. aThe error in the last digit is shown in the parentheses. 
 
Once the pKa values of the ligands were determined, the solution speciation experiments of 
Cu(II)–/Zn(II)–ligand complexes were carried out in a pH range of 3.5-8. The dissociation constants 
(Kd ≈ [Cuunchelated] or [Znunchelated]; pCu = –log[Cuunchelated]; pZn = –log[Znunchelated]) of Cu(II) or Zn(II) 
complexes with the bpy derivatives were identified based on the stability constants (log) and the 
pCu and pZn values (Figures 2.4 and 2.5). In the pH range, the speciation studies of Cu(II) and Zn(II) 
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complexes with bpy and 1–4 indicated the presence of Cu(II)– or Zn(II)–ligand complexes with the 
1:1 and/or 1:2 metal-to-ligand stoichiometry at pH 7.4 (Figures 2.4 and 2.5). As for the metal binding 
affinities of the bpy derivatives at a physiological pH (i.e., 7.4), 1–3 were observed to have binding 
affinities to Cu(II) and Zn(II) in the nanomolar and low micromolar range, respectively, except for 4 
(micromolar and high micromolar for Cu(II) and Zn(II), respectively). The metal binding affinities of 
bpy derivatives were determined to be altered due to the changed electron density on the N donor 
atoms, responsible for metal chelation, by the incorporation of the dimethylamino and/or methyl 
group(s). In addition, in both Cu(II)- and Zn(II)-containing experimental sets, 4, containing a methyl 
group located at the ortho position to the N donor atom on a pyridine ring (steric hindrance), exhibited 
the weakest binding affinities for both metal ions, compared to the other derivatives (1–3), as 
expected. Collecting these results, the methyl substituent’s position on the bpy framework, along with 
installation of a dimethylamino group, is a factor in varying the binding affinities of the bpy 
derivatives to Cu(II) and Zn(II). Overall, the Kd values of Cu(II)– and Zn(II)–ligand (i.e., bpy and 1–3) 
complexes were within the appropriate range for interaction with metal ions surrounded by A [Kd, ca. 
10–12–10–9 M for Cu(II)–A; Kd, ca. 10–9–10–6 M for Zn(II)–A],4,6,10,11 while those of 4 were not 
within this range, suggesting that bpy and 1–3 could affect metal–A aggregation pathways (vide 
infra). 
 
2.2.3. Interactions of bpy Derivatives with Metal-free A and Metal–A.  
Electrospray ionization mass spectrometry (ESI-MS) was employed to investigate how the bpy 
derivatives interact with A in the absence and presence of Cu(II). Note that Zn(II)–A complexes 
were not detectable under our MS conditions. As shown in Figure 2.6a, upon incubation of bpy, 1, 
and 4 with metal-free A40, the MS spectra did not indicate compound–A interactions, such as A–
ligand adduct formation and peptide modifications (i.e., oxidation, cleavage), suggested mechanisms 
for modulating A aggregation.21,25,27,28,34,35 
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Figure 2.6. ESI-MS spectra of A40 incubated with excess amounts of compounds (bpy, 1, and 4) in 
the absence and presence of Cu(II). ESI-MS spectra of A40 without (a) and with (b) Cu(II). 
Conditions: [A40] = 100 M; [CuCl2] = 100 M; [compound] = 500 M; 20 mM ammonium acetate, 
pH 7.2 (1% v/v DMSO); 37 °C; 1 h incubation; no agitation; 10-fold diluted samples were injected to 
the mass spectrometer. (c) Tandem MS (ESI-MS2) spectrum of the +4-charged ternary complex ([A40 
+ Cu(II) + 1 + 2H]4+, 1148 m/z). The ESI-MS2 results support the formation of a ternary complex 
composed of A40, Cu(II), and 1. The relative abundance of each spectrum was individually 
normalized based on the highest peak.  
 
 
 
 
Figure 2.7. Tandem MS (ESI-MS2) spectrum of the +4-charged peak at 1151 m/z from the sample 
containing A40, Cu(II), and 4. The ESI-MS2 results supported that the peak was assigned to [A+ 
2Cu + 2K + 4H2O – 2H]4+, thus indicating no formation of a ternary complex composed of A40, 
Cu(II), and 4. Conditions: [A40] = 100 M; [CuCl2] = 100 M; [compound] = 500 M; 20 mM 
ammonium acetate, pH 7.2 (1% v/v DMSO); 37 °C; 1 h incubation; no agitation; the 10-fold diluted 
samples were injected to the mass spectrometer. The relative abundance of each spectrum was 
individually normalized based on the highest peak.  
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As depicted in Figure 2.6b, a noticeable decrease in the relative abundance of Cu(II)–A40 
(assigned as red peaks) in the ESI-MS spectra was monitored when Cu(II)–A40 samples were treated 
with bpy, 1, or 4. The observed reduction in the signal of Cu(II)–A40 may be accounted for by two 
possible explanations: (i) bpy, 1, and 4 may accelerate the Cu(II)–A aggregation, thus significantly 
decreasing the amount of monomeric Cu(II)–A present in solution; (ii) bpy, 1, and 4 may sequester 
Cu(II) from Cu(II)–A potentially altering metal–A aggregation pathways. Additionally, the 
production of a ternary complex [i.e., Cu(II)–A40–1, 1148 m/z] was verified by ESI-MS from Cu(II)–
A40 samples treated with 1 (Figure 2.6b; green peak). The tandem MS (ESI-MS2) analysis of the 
ternary complex indicated the peaks denoting ions of Cu(II)–A40, metal-free A40, and 1 (Figure 
2.6c). Based on the detection of the Cu(II)–A40–1 complex, the incorporation of the dimethylamino 
functionality seems to markedly promote the interaction between the ligand and metal–Aas 
expected. Furthermore, based on previously reported studies,21,24,28 the generation of a ternary 
complex composed of 1 and Cu(II)–A proposes its capability of modifying metal–A aggregation 
pathways (vide infra). In contrast, as depicted in Figure 2.6b, the presence of the remaining Cu(II)–
A40 peak was detected in the sample of Cu(II)–A40 treated with 4. The expected m/z value (1151 
m/z) for a ternary complex composed of Cu(II)–A40 and 4 was observed by ESI-MS (Figure 2.6b); 
however, our ESI-MS2 analysis indicated that the peak contained A40 and Cu(II) without 4 (Figure 
2.7), thus being assigned as [A40 + 2Cu + 2K + 4H2O – 2H]4+ (no generation of a ternary complex 
between metal–A and 4). Overall, these different interactions of 1 and 4 with A in the presence of 
Cu(II) could be correlated with their metal binding affinities affecting their ability to bind to Cu(II) 
surrounded by A (vide supra). Taken together, the ESI-MS and ESI-MS2 studies suggest that the 
introduction of the dimethylamino functionality onto the bpy backbone could enhance the molecule’s 
interaction with Cu(II)–A. Additionally, the varied metal binding properties of the bpy derivatives 
through the inclusion of a methyl group on the framework were shown to be related to their ability to 
interact with Cu(II)–A. Such differentiated degrees of interaction between the bpy derivatives and 
Cu(II)–A, along with no apparent interaction with metal-free A, could be a corresponding feature 
directing their controlling reactivity towards metal–A aggregation over metal-free A analog (vide 
infra). 
 
2.2.4. Effects of bpy Derivatives on Aggregation of Metal-free A and Metal–A.  
In order to identify the ability of the bpy derivatives to regulate A aggregation in both the absence 
and presence of metal ions [i.e., Cu(II) and Zn(II)], experiments able to indicate their influence on the 
formation of A aggregates upon treatment with compounds were performed (Figure 2.8a). We 
employed gel electrophoresis with Western blotting (gel/Western blot) utilizing an anti-A antibody 
㸯㸷 
 
(6E10) and transmission electron microscopy (TEM) to analyze the MW distributions and 
morphological changes of the resultant A species upon incubation with the bpy derivatives, 
respectively (Figures 2.8 and 2.9). Under our experimental conditions, compound-free A samples 
with and without metal ions are generally observed to produce aggregates with high MWs (e.g., fibrils) 
that are too bulky to penetrate the gel matrix, yielding a small amount of smearing in the gels.27,28,34,35 
These large-sized A aggregates were visualized via TEM.27,28,34,35  
 
 
 
Figure 2.8. Effects of bpy and 1–4 towards formation of metal-free A and metal–A aggregates. (a) 
Scheme of the experiments. (b) Visualization of the resultant A40 and A42 species by gel 
electrophoresis with Western blotting (gel/Western blot) using an anti-A antibody (6E10). 
Conditions: [A] = 25 M; [CuCl2 or ZnCl2] = 25 M; [compounds] = 50 M; 24 h; pH 6.6 (for 
Cu(II)-treated experiments) or pH 7.4 (for metal-free and Zn(II)-added experiments); 37 °C; constant 
agitation. Lanes: (C) [A (± CuCl2 or ZnCl2)]; (B) [(C) + bpy]; (1) [(C) + 1]; (2) [(C) + 2]; (3) [(C) + 
3]; (4) [(C) + 4]. (c) TEM images of the 24 h incubated A40 samples from (b) [the TEM images of 
the resultant A42 aggregates from (b) are presented in Figure 2.9]. The insets represent the minor 
species. Scale bar = 200 nm. 
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As shown in Figure 2.8b (left column), the gel/Western blot results demonstrated that bpy and its 
derivatives did not exhibit any reactivity against both A40 and A42 in the absence of metal ions. The 
MW distributions of Cu(II)–A40/A42 species, but not Zn(II)–A40/A42 species, were altered with 
the treatment of bpy (Figure 2.8b, middle and right columns, lane B). On the other hand, the 
compounds embodying the dimethylamino functionality (i.e., 1–3; except for 4) were able to 
noticeably vary the sizes of both Cu(II)–A40/A42 species and Zn(II)–A40/A42 species to different 
extents, indicating the generation of a mixture of peptide species with various MWs (Figure 2.8b, 
middle and right columns, lanes 1-3). As expected from the studies of metal binding and metal–A 
interaction (vide supra), 4 did not show its perceivable activity in modulation of both Cu(II)–
A40/A42 and Zn(II)–A40/A42 aggregation (Figure 2.8b, middle and right columns, lane 4).  
 
 
 
Figure 2.9. TEM images of the resultant metal-free A42 and metal–A42 aggregates generated upon 
treatment with bpy and 1–4. (a) Scheme of the experiments. (b) TEM images of the 24 h incubated 
A42 samples from Figure 2.8. Scale bar = 200 nm. 
 
In addition to the gel/Western blot, the morphologies of both resultant A40 and A42 aggregates 
upon addition of bpy and 1–4 were analyzed by TEM. As presented in Figures 2.8c and 2.9b (left 
column), metal-free A aggregates produced by incubation with bpy or 1–4 were shown to have 
similar morphologies to those generated under compound-free conditions. Different from metal-free 
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conditions, Cu(II)–A samples treated with bpy demonstrated smaller unstructured aggregates, but no 
significant morphological variation of the bpy-treated Zn(II)–A aggregates was revealed (Figures 
2.8c and 2.9b, middle and right columns). In both Cu(II)–A and Zn(II)–A samples containing 1–3, 
peptide aggregates with distinctive morphologies (i.e., thinner/shorter fibers and amorphous species), 
compared to those from compound-free metal–A samples, were exhibited (Figures 2.8c and 2.9b, 
middle and right columns). On the contrary, 4 could not affect the morphologies of the resultant A 
aggregates under metal-treated conditions (Figures 2.8c and 2.9b)SG as expected from its lack of 
interaction with metal–Aand modulation of metal–A aggregation, demonstrated by the ESI-MS 
and gel/Western blot experiments, respectively (Figures 2.6b and 2.8b). 
Based on the overall observations, both the dimethylamino and methyl groups are indicated to 
alter the compounds’ ability to control the aggregation pathways of metal-treated A40 and A42. To be 
more specific, the bpy derivatives (1–3) containing a dimethylamino moiety with proper metal 
binding affinities were shown to have their regulatory reactivity against A aggregation in the 
presence of Cu(II) and Zn(II). Although 4’s structure includes the dimethylamino functionality (like 
1–3), the methyl group at the ortho position to the N donor atom of a pyridine ring appears to change 
its metal binding affinities thus hampering the compound’s capacity to impact metal–A aggregation 
pathways. 
 
2.2.5. Biological Properties of bpy Derivatives.  
In addition to their in vitro reactivity towards metal–A, the potential of our bpy derivatives to be 
used in biological systems was investigated. For potent applications in brain, BBB permeability of the 
bpy derivatives was analyzed. As summarized in Table 1, based on Lipinski’s rules, calculated logBB 
values (logBB = logarithm of the ratio between the concentration of a drug in the brain and that in the 
blood), and the –logPe values measured by the in vitro parallel artificial membrane permeability assay 
adapted for the BBB (PAMPA–BBB),45-47 the bpy derivatives were suggested to be BBB permeable. 
 
Table 2.1. Values (MW, clogP, HBA, HBD, PSA, logBB, and –logPe)a for bpy and 1–4. 
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aMW, molecular weight; clogP, calculated logarithm of the octanol-water partition coefficient; HBA, 
the number of hydrogen bond acceptor atoms; HBD, the number of hydrogen bond donor atoms; PSA, 
polar surface area; logBB ൌ  െ0.0148 ൈ  PSA ൅  0.152 ൈ  clogP ൅  0.139 (logBB ൏  െ1.0, 
poorly distributed in the brain); െlogPe values, determined using the PAMPA-BBB assay, were 
calculated by PAMPA 9 explorer software v. 3.5. Compounds assigned to be CNS+ possess the 
ability to penetrate the BBB while those categorized as CNSȂ are expected to have poor BBB 
permeability. 
 
Moreover, the toxicity of bpy derivatives was determined in human neuroblastoma SH-SY5Y 
(5Y) cells. Approximately 80% of cell survival was observed when 5Y cells were treated with the bpy 
derivatives (up to 50 M) without metal ions for 24 h (Figure 2.10). In the presence of Zn(II) (5 or 10 
M), the bpy derivatives (up to 10 M) exhibited ca. 85% of cell viability; however, upon incubation 
with Cu(II) (5 or 10 M), they presented relatively moderate cytotoxicity (ca. 70% of cell survival; 
Figure 2.11). Note that due to compounds’ toxicity with Cu(II), their ability to regulate toxicity 
triggered by metal–A was not evaluated in living cells. 
 
 
 
Figure 2.10. Toxicity of bpy and 1–4 in SH-SY5Y cells. Cells were treated with bpy or 1–4 for 24 h 
at 37 °C. Cell viability (%) was determined by the MTT assay. The viability values were calculated 
compared to those of cells added with DMSO only (1%, v/v). Error bars represent the standard error 
from three independent experiments (P < 0.05).  
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Figure 11. Toxicity of bpy and 1–4 in SH-SY5Y cells in the presence of metal ions. Cells were 
treated with bpy or 1–4 (10 M) with metal ions (5 or 10 M) for 24 h at 37 °C. Cell viability (%) 
was determined by the MTT assay. The viability values of cells were calculated compared to those of 
cells added with DMSO only (1%, v/v). Error bars represent the standard deviation from three 
independent experiments (P < 0.05). 
 
2.3. Conclusions 
Through a structure-based approach, new bpy derivatives (1–4) were rationally designed as chemical 
tools able to regulate metal–A aggregation. The newly designed bpy derivatives were indicated to 
bind with Cu(II) and Zn(II) exhibiting different metal binding affinities, especially dependent on the 
location of the methyl substituent in the bpy framework. Moreover, our mass spectrometric studies 
presented the direct interactions, including the formation of a ternary Cu(II)–A–1 complex, of the 
bpy derivatives with Cu(II)–A over metal-free A. The structural modifications of bpy (i.e., 
introduction of dimethylamino and methyl moieties) varied the characteristics of both metal binding 
and A interaction, enabling the interaction between its derivatives and metal–A, which in turn 
exhibited their noticeable reactivity towards control of metal–A aggregation over metal-free A 
analog. Alteration of metal-induced A aggregation was also indicated by previously reported metal 
chelators, including 8-hydroxyquinoline (8-HQ) derivatives [i.e., 8-HQ, clioquinol (CQ), PBT2].7,18,48 
Different from 8-HQ-based ligands shown to remove metal ions from metal–A species, however, 
modulation of our bpy derivatives towards metal–A aggregation is suggested to occur through 
chelating out metal ions from metal–A species as well as forming a ternary complex with metal–A. 
In order to fully elucidate how our bpy derivatives interact with A and modulate A aggregation, 
high-resolution structural studies with A would be valuable to be pursued in the future. Our bpy 
derivatives were suggested to be BBB permeable but they displayed cytotoxicity at micromolar 
concentrations of Cu(II). Thus, further structural optimization of the derivatives is necessary for 
potential biological applications. Taken together, our studies demonstrate that chemical tools able to 
regulate metal–A aggregation over metal-free A analog can be developed via rational structure-
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based design employing a backbone of a simple metal chelator. Our straightforward structural 
variations onto known metal chelating agents could be easily utilized to invent small molecules as 
chemical tools capable of interacting and reacting with metal-associated biological targets. 
 
2.4. Experimental Section 
2.4.1. Materials and Methods  
All reagents were purchased from commercial suppliers and used as received unless otherwise noted. 
The ligand, bpy, was purchased from Sigma-Aldrich (St. Louis, MO, USA) and used without further 
purification. NMR and high-resolution mass spectrometric analyses of small molecules were 
conducted on an Agilent 400-MR DD2 NMR spectrometer (UNIST Central Research Facilities, Ulsan, 
Republic of Korea) and Q exactive plus orbitrap mass spectrometer (HRMS; Thermo Fisher Scientific, 
Waltham, MA, USA). Absorbance values for biological assays were measured on a Molecular 
Devices SpectraMax M5e microplate reader (Sunnyvale, CA, USA). Trace metal contamination was 
removed from buffers and solutions used for metal binding and A experiments by treating with 
Chelex overnight (Sigma-Aldrich, St. Louis, MO, USA). Optical spectra were recorded on an Agilent 
8453 UV−vis spectrophotometer. A40 and A42 were purchased from Anygen (A40 = 
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGL-MVGGVV; Nam-myun, Jangseong-gun, 
Republic of Korea) and AnaSpec (A42 = DAEFRHDSGYEVH-
HQKLVFFAEDVGSNKGAIIGLMVGGVVIA; Fremont, CA, USA), respectively. Double-distilled 
H2O (ddH2O) was obtained from a Milli-Q Direct 16 system (Merck KGaA, Darmstadt, Germany). 
ESI-MS and tandem MS analyses were performed using a Waters Synapt G2-Si quadrupole time-of-
flight (Q-TOF) ion mobility mass spectrometer equipped with an ESI source (DGIST Center for Core 
Research Facilities, Daegu, Republic of Korea). TEM images were taken using a JEOL JEM-2100 
transmission electron microscope (UNIST Central Research Facilities, Ulsan, Republic of Korea). 
 
2.4.2. Synthesis Preparation  
All reactions were carried out in flame or oven dried glassware under nitrogen atmosphere with 
freshly distilled dry solvents under anhydrous conditions unless otherwise indicated. Flash column 
chromatography was performed with silica gel 60 (230–400 mesh). Thin layer chromatography (TLC) 
plates were visualized by fluorescence quenching with UV light at 254 nm or by staining using base 
solution of potassium permanganate and molybdate. All reagents were obtained from commercial 
sources and were used without further purification. 
 
2.4.3. N,N-Dimethyl-2-(tributylstannyl)pyridin-4-amine  
To a solution of 2-dimethylamino-ethanol (146 mg, 1.64 mmol) in hexanes (4 mL) at –5 °C was added 
dropwise 2 M solution of n-BuLi (1.7 mL, 3.28 mmol) under nitrogen atmosphere and stirred at 0 °C 
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for 30 min. The solution was treated with 4-dimethylaminopyridine (100 mg, 0.8 mmol), stirred at 
0 °C for 1 h, and cooled down to –78 °C. After addition of Bu3SnCl (533 mg, 1.64 mmol), the 
reaction mixture was stirred at 0 °C for 1 h. The reaction mixture was quenched with water, and the 
aqueous phase was extracted with ether three times. The combined organic layers were dried over 
MgSO4, filtered, and concentrated under reduced pressure. The crude product was purified by column 
chromatography using EtOAc as an eluent to give the stannylated product (78%) (EtOAc/NEt3 = 99:1; 
Rf = 0.56). 1H NMR (400 MHz, CDCl3) /  (ppm): 0.88 (9H, t, J = 7.3 Hz), 1.09 (6H, m), 1.33 (6H, dq, 
J = 14.5, 7.3 Hz), 1.57 (6H, dt, J = 15.8, 7.9 Hz), 2.97 (6H, s), 6.38 (1H, dd, J = 6.0, 2.9 Hz), 6.64 (1H, 
d, J = 2.9 Hz), 8.34 (1H, d, J = 6.0 Hz). 13C NMR (100 MHz, CDCl3) /  (ppm): 9.7, 13.7, 27.4, 29.2, 
38.9, 105.4, 115.5, 150.1, 152.1, 172.0. ESI-MS: Calcd for C19H36N2Sn [M + H]+, 413.2; found 413.2. 
 
2.4.4. General Procedure for 1–4 
To a solution of N,N-dimethyl-2-(tributylstannyl)pyridin-4-amine (95 mg, 0.23 mmol) in toluene (2.5 
mL) under nitrogen atmosphere was added PdCl2(PPh3)2 (8 mg, 0.0115 mmol), LiCl (29 mg, 0.69 
mmol), PPh3 (6 mg, 0.023 mmol) and the appropriate bromide (2-bromopyridine, 2-bromo-n-
methylpyridine, n = 4, 5, and 6; 1.2 mmol) and heated at 110 °C for 24 h. The reaction mixture was 
concentrated and purified by column chromatography. 
 
2.4.5. N,N-Dimethylamino-(2,2’-bipyridin)-4-amine (1)  
This compound was isolated by using column chromatography (EtOAc/NEt3) as a white solid (50%). 
Rf (EtOAc/NEt3 = 95:5) = 0.2. 1H NMR (400 MHz, CD2Cl2) /  (ppm): 3.09 (6H, s, N-CH3), 6.56 (1H, 
dd, J = 5.9, 2.7 Hz, H5), 7.29 (1H, ddd, J = 7.5, 4.8, 1.2 Hz, H5’), 7.75 (1H, d, J = 2.7 Hz, H3), 7.80 
(1H, td, J = 7.8, 1.8 Hz, H4’), 8.28 (1H, d, J = 5.9 Hz, H6), 8.40 (1H, dt, J = 8.0, 1.0 Hz, H6’), 
8.63(1H, ddd, J = 4.8, 1.7, 0.9 Hz, H3’). 13C NMR (100 MHz, CDCl3) /  (ppm): 39.1 (N-CH3), 103.4 
(C5), 106.6 (C3), 120.9 (C3’), 123.3 (C5’), 136.5 (C6), 148.7 (C4’), 149.2 (C6’), 155.2 (C2’), 155.9 
(C2), 156.8 (C4). HRMS: Calcd for C12H14N3 [M + H]+, 200.1182; found 200.1180. 
 
2.4.6. N,N,4’-Trimethyl-(2,2’-bipyridin)-4-amine (2)  
This compound was obtained by using column chromatography (EtOAc/NEt3) as a white solid (33%). 
Rf (EtOAc/NEt3 = 99 :1) = 0.3. 1H NMR (400 MHz, CD2Cl2) /  (ppm): 2.43 (3H, s, CH3), 3.09 (6H, s, 
N-CH3), 6.55 (1H, dd, J = 5.8, 2.7 Hz, H5), 7.12 (1H, d, J = 4.4 Hz, H5’), 7.74 (1H, d, J = 2.7 Hz, H3), 
8.27 (2H, d, J = 5.9 Hz, H6 and H6’), 8.48 (1H, d, J = 4.9 Hz, H3’). 13C NMR (100 MHz, CD2Cl2) /  
(ppm): 20.9 (CH3), 39.1 (N-CH3), 103.5 (C5), 106.5 (C3), 121.7 (C5’), 124.3(C3’), 147.8 (C6), 148.5 
(C4’), 149.1 (C6’), 152.2 (C2), 156.0 (C2’), 156.6 (C4). HRMS: Calcd for C13H16N3 [M + H]+, 
214.1339; found 214.1337. 
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2.4.7. N,N,5’-Trimethyl-(2,2’-bipyridin)-4-amine (3) 
This compound was isolated by using column chromatography (EtOAc/NEt3) as a white solid (42%). 
Rf (EtOAc/NEt3 = 99 :1) = 0.2. 1H NMR (400 MHz, CD2Cl2) /  (ppm): 2.38 (3H, s, CH3), 3.09 (6H, s, 
N-CH3), 6.54 (1H, dd, J = 5.9, 2.7 Hz, H5), 7.61 (1H, ddd, J = 8.1, 2.2, 0.6 Hz, H4’), 7.71 (1H, d, J = 
2.7 Hz, H3), 8.26 (1H, d, J = 5.9 Hz, H6), 8.29 (1H, d, J = 8.1 Hz, H6’), 8.46 (1H, m, H3’). 13C NMR 
(100 MHz, CD2Cl2) /  (ppm): 18.0 (CH3), 39.1 (N-CH3), 103.1 (C5), 106.4 (C3), 120.4 (C3’), 133.1 
(C5’), 137.1 (C6), 148.9 (C4’), 149.2 (C6’), 154.1 (C2’), 155.2 (C2), 155.9 (C4). HRMS: Calcd for 
C13H16N3 [M + H]+, 214.1339; found 214.1337. 
 
2.4.8. N,N,6’-Trimethyl-(2,2’-bipyridin)-4-amine (4) 
This compound was isolated by using column chromatography (EtOAc/NEt3) as a white solid (38%). 
Rf (EtOAc/NEt3 = 99 :1) = 0.15. 1H NMR (400 MHz, CD2Cl2) /  (ppm): 2.61 (3H, s, CH3), 3.09 (6H, 
s, N-CH3), 6.55 (1H, dd, J = 5.9, 2.8 Hz, H5), 7.16 (1H, d, J = 7.6 Hz, H5’), 7.68 (1H, t, J = 7.7 Hz, 
H4’), 7.75 (1H, d, J = 2.7 Hz, H3), 8.17 (1H, d, J = 7.9 Hz, H3’), 8.27 (1H, d, J = 5.9 Hz, H6). 13C 
NMR (100 MHz, CD2Cl2) /  (ppm): 24.3 (CH3), 39.4 (N-CH3), 103.4 (C5), 106.5 (C3), 117.9 (C5’), 
122.7 (C3’), 136.7 (C6), 149.1 (C4’), 155.2 (C2), 156.2 (C4), 157.5 (C2’ and C6’). HRMS: Calcd for 
C13H16N3 [M + H]+, 214.1339; found 214.1336. 
 
2.4.9. Parallel Artificial Membrane Permeability Adapted for the Blood–Brain Barrier 
(PAMPA-BBB) Assay 
PAMPA-BBB experiments of compounds were conducted using the PAMPA Explorer kit (pION, Inc. 
Billerica, MA, USA) with slight modifications of previously reported protocols.21,25,28,45-47 Each 
compound stock solution was diluted with Prisma HT buffer (pH 7.4; pION) to a final concentration 
of 25 M [1% v/v dimethyl sulfoxide (DMSO)] and was added to the wells of the donor plate (200 L, 
number of replicates = 12). BBB-1 lipid formulation (5 L, pION) was used to coat the 
polyvinylidene fluoride (PVDF, 0.45 M) filter membrane on the acceptor plate. The acceptor plate 
was placed on top of the donor plate, forming a sandwich, and the brain sink buffer (BSB, 200 L, 
pION) was added to each well of the acceptor plate. The sandwich was incubated for 4 h at ambient 
temperature without stirring. UV−vis spectra of the solutions in the reference, acceptor, and donor 
plates were measured on a microplate reader. The PAMPA Explorer software, v. 3.5 (pION), was 
used to calculate the value of –logPe for each compound. CNS± designations were assigned by 
referring to compounds that were identified in previous reports.45-47 
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2.4.10. Metal Binding Experiments 
Metal binding of bpy and 1–4 was investigated by UV−vis. UV−vis experiments were carried out in 
the Chelex-treated buffered solution (20 M HEPES, pH 7.4, 150 M NaCl). To a solution of a ligand, 
CuCl2 or ZnCl2 was titrated up to 5 equiv at room temperature. The solution was stabilized to 
equilibrate for 5 min after addition of compounds. The spectra were recorded after 5 min incubation at 
room temperature. 
 
2.4.11. Solution Speciation Studies 
The pKa values for bpy and 1–4 were determined through UV−vis variable-pH titrations based on 
previously reported procedures.21,27,28 To obtain pKa values for compounds, the solution of compound 
(25 M; 10 mM NaOH, pH 12, 100 mM NaCl) was titrated with in small aliquots of HCl to obtain at 
least 30 spectra in a range of pH 3.5 to 10. In addition, to determine the binding affinities of 
compounds to Cu(II) or Zn(II), small aliquots of HCl were titrated into their solution containing 
ligand and a metal chloride salt [[M(II)]:[L] = 1:2; [Cu(II)] = 12.5 M, [Zn(II)] = 12.5 (for bpy and 
1–3) or 50 M (for 4)]. At least 30 spectra were acquired over the pH range (3.5−8). The acidity and 
stability constants were calculated by the HypSpec program (Protonic Software, Leeds, UK).49,50 
 
2.4.12. Electrospray Ionization Mass Spectrometry (ESI-MS) 
A40 (100 M) was incubated with compounds (bpy and 1–4, 500 M) for 1 h at 37 °C without 
agitation [20 mM ammonium acetate, pH 7.2 (with 1% v/v DMSO)] in the absence and presence of 
CuCl2 (100 M). Before the injection of samples into the mass spectrometer, the incubated samples 
were diluted by 10 fold. ESI-MS analysis was performed using the Synapt G2-Si Q-TOF mass 
spectrometer (Waters, Manchester, UK) equipped with ESI source. The capillary voltage, sampling 
cone voltage, and source temperature were set to 2.8 kV, 40 V, and 40 °C, respectively. Tandem MS 
analysis was also performed based on the same instrumental conditions. The isolation width was set 
as approximately 5 by adjusting low mass resolution to 4.7, and 15 eV collision energy was applied to 
the trap cell to dissociate the precursor ion. 
 
2.4.13. A Aggregation Experiments 
All experiments were performed according to previously published methods.21,27,28,34 Prior to 
experiments, A40 or A42 was dissolved in ammonium hydroxide (NH4OH, 1% v/v, aq), aliquoted, 
lyophilized overnight, and stored at −80 °C. For experiments described herein, a stock solution of A 
was prepared by dissolving the lyophilized peptide in 1% NH4OH (10 L) and diluting with ddH2O. 
The concentration of A was determined by measuring the absorbance of the solution at 280 nm (	 = 
1450 M−1 cm−1 for A40; 	 = 1490 M−1 cm−1 for A42). The peptide stock solution was diluted to a 
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final concentration of 25 M in the Chelex-treated buffered solution containing HEPES [20 M; pH 
7.4 (for metal-free and Zn(II) samples) or pH 6.6 (for Cu(II) samples)] and NaCl (150 M). For the 
studies, a compound (final concentration, 50 M; 1% v/v DMSO) was added to the sample of A (25 
M) in the absence and presence of a metal chloride salt (CuCl2 or ZnCl2; 25 M) followed by 
incubation for 24 h at 37 °C with constant agitation. 
 
2.4.14. Gel Electrophoresis with Western Blot 
The samples from A experiments were analyzed by gel electrophoresis with Western blotting using 
an anti-A antibody (6E10).21,27,28,34 Each sample (10 L) was separated on a 10−20% Tris-tricine gel 
(Thermo Fisher Scientific, Carlsbad, CA, USA). Following separation, the proteins were transferred 
onto nitrocellulose membrane, which was blocked with bovine serum albumin (BSA, 3% w/v, 
RMBIO, Missoula, MT, USA) in Tris-buffered saline (TBS) containing 0.1% Tween-20 (TBS-T) for 
2 h at room temperature. The membranes were incubated with the antibody (6E10), (1:2,000; Covance, 
Princeton, NJ, USA) in a solution of 2% BSA (w/v in TBS-T) overnight at 4 °C. After washing, the 
horseradish peroxidase-conjugated goat antimouse secondary antibody (1:5,000) in 2% BSA was 
added for 1 h at room temperature. A homemade ECL kit51 was used to visualize the results on a 
ChemiDoc MP Imaging System (Bio- Rad, Hercules, CA, USA). 
 
2.4.15. Transmission Electron Microscopy (TEM) 
Samples for TEM were prepared according to previously reported methods.21,27,28,34,35 Glow-
discharged grids (Formvar/Carbon 300-mesh, Electron Microscopy Sciences, Hatfield, PA, USA) 
were treated with A samples from the experiments (5 L) for 2 min at room temperature. Excess 
sample was removed using filter paper followed by washing three times with ddH2O. Each grid was 
incubated with uranyl acetate (1% w/v ddH2O, 5 L) for 1 min. Upon removal of excess uranyl 
acetate with filter paper, the grids were dried for at least 20 min at room temperature before 
measurement. Images from each sample were taken on a JEOL JEM-2100 transmission electron 
microscope (200 kV; 25,000x magnification). 
 
2.4.16. Cell Viability Measurements 
The human neuroblastoma SH-SY5Y cell line was purchased from the American Type Cell 
Collection (ATCC, Manassas, VA, USA). Cells were maintained in media containing 1:1 Minimum 
Essential Media (MEM; GIBCO, Grand Island, NY, USA) and Ham’s F12K Kaighn’s Modification 
Media (F12 K; GIBCO), 10% (v/v) fetal bovine serum (FBS; GIBCO), and 1 U/mL penicillin 
(GIBCO). The cells were grown and maintained at 37 °C in a humidified atmosphere with 5% CO2. 
Cell viability upon treatment with compounds was determined by the MTT assay [MTT = 3-(4,5-
㸰㸷 
 
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide, Sigma-Aldrich]. SH-SY5Y cells were 
seeded in a 96 well plate (15,000 cells in 100 L per well). The cells were treated with compounds (5 
or 10 M, 1% v/v final DMSO concentration) with or without CuCl2 or ZnCl2 (5 or 10 M), and 
incubated for 24 h. After incubation, MTT [25 L; 5 mg/mL in phosphate buffered saline (PBS, pH 
7.4, GIBCO)] was added to each well, and the plate was incubated for 4 h at 37 °C. Formazan 
produced by the cells was solubilized using an acidic solution of N,N-dimethylformamide (DMF, 50% 
v/v aq) and sodium dodecyl sulfate (SDS, 20% w/v) overnight at room temperature in the dark. The 
absorbance was measured at 600 nm using a microplate reader. Cell viability was calculated relative 
to cells treated with an equivalent amount of DMSO. All experiments were carried out in triplicate. 
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Synthesis of FosB Inhibitor  
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A.1. introduction 
The FosB is a transcription factor, kind of leucine zipper working dimeric form.1 It is accumulated in 
striatum of the brain, and related in gene expression and accumulates in human body.1,2 The elevated 
levels of FosB are thought to mediate long-lasting neural and behavioral changes in response to drug 
addiction and dyskinesia.3-5 The FosB also mediates endogenous resilience or handling mechanisms 
of stress.6 To inhibit the elevated level of FosB, large number of small molecules were screened.7  
Two active analogues were identified to inhibit FosB with micromolar concentration of IC50 
value.7 The IC50 values of them were too high to apply in the human body.7 For increasing their 
reactivity, structures of small molecules were modified.7 To enhance the reactivity of FosB inhibitor, 
structure variations were applied to FosB inhibitors.7 The newly prepared molecules, however, were 
shown slightly better IC50 value with before or poorer.7 Herein, the design and synthesis of FosB 
inhibitor which two reactive moiety connected by linker will be described. 
 
A.2. Result and Discussion 
To enhance the IC50 value, structure modified molecules were prepared and tested, however, the IC50 
values of them are still shown micromolar range.7 For better reactivity, two individual FosB inhibitor 
(C6) are connected by linker. The C6 are connected by linker (e.g., different length of alkyl chain). 
First, (Z)-5-(5-hydroxy-2-nitrobenzylidene)-2-thioxo-thiazolidin-4-one (C6-OH) were prepared by 
Knoevenagel condensation reaction with the 5-hydroxy-2-nitrobenzaldehyde and 2-thioxothiazolidin-
4-one.8,9 C6-OH was then deprotonated in the KOH solution to produce the potassium (Z)-4-nitro-3-
((4-oxo-2-thioxothiazolidin-5-ylidene)methyl)phenolate (C6-OK). The (5Z,5'Z)-5,5'-(((butane-1,4-
diylbis(oxy))bis(6-nitro-3,1-phenylene))bis(methanylylidene))bis(2-thioxothiazolidin-4-one) (C6-
n2m) and 5-((Z)-5-hydroxy-2-nitrobenzylidene)-3-(10-(4-nitro-3-((Z)-(4-oxo-2-thioxothiazolidin-5-
ylidene)methyl)phenoxy)decyl)-2-thioxothiazolidin-4-one (C6-n4m) was constructed by Williamson 
ether synthesis C6-OK with either 1,4-dibromobutane or 1,10-dibromodecane respectively as shown 
in scheme A.1.10 
 
Shceme A.1. Synthetic routes to C6-n2m and C6-n4m. 
 
Ragents and conditions: (i) -alanine, acetic acid, 100 °C, yield: 72%; (ii) KOH, EtOH, rt, yield: 37%; 
(iii) DMF, 80 °C, yield: 27%. 
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A.3. Experimental Section 
A.3.1. Syntheses 
The compounds, 5-hydroxy-2-nitrobenzaldehyde and 2-thioxothiazolidin-4-one were purchased from 
alfa aesar, 1,4-dibromobutane and 1,10-dibromodecane were purchased from TCI chemicals. 
 
A.3.2. (Z)-5-(5-hydroxy-2-nitrobenzylidene)-2-thioxothiazolidin-4-one (C6-OH) 
A solution of acetic acid (15 mL) was added 5-hydroxy-2-nitrobenzaldehyde (517 mg, 3 mmol), 2-
thioxothiazolidin-4-one (815 mg, 6 mmol), and -alanine (847 mg, 6 mmol). The reaction mixture 
was heating to 100 °C with stirring for 3 h. After 3 h, the reaction mixture was cooling down in the ice 
bath. Generated powder was filtered and washing with water. The powder was recrystallized in 
acetone/H2O to afford the product (yellow powder, 610 mg, 2.16 mmol, 72% yield). 1H NMR (400 
MHz, (CD3)2SO /  (ppm): 13.89 (1H, s), 11.31 (1H, s), 8.14 (1H, d, J = 8.83 Hz), 7.88 (1H, s), 6.98 
(2H, m). 
 
Figure A.1. 1H NMR spectrum of C6-OH [400 MHz, (CD3)2SO] 
 
A.3.3. Potassium (Z)-4-nitro-3-((4-oxo-2-thioxothiazolidin-5-ylidene)methyl)phenolate (C6-OK) 
A solution of EtOH (15 mL) was added KOH (140 mg, 2.48 mmol) and (Z)-5-(5-hydroxy-2-
nitrobenzylidene)-2-thioxothiazolidin-4-one (C6-OH) (642 mg, 2.27 mmol). The reaction mixture 
was allowed to stir for 3 h. The product was filtered and washed with EtOH (orange powder, 268 mg, 
0.84 mmol, 37% yield). 1H NMR (400 MHz, (CD3)2SO /  (ppm): 7.91 (1H, d, J = 9.29 Hz), 7.50 (1H, 
s), 6.53 (1H, s), 6.41 (1H, d, J = 9.23 Hz). 
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Figure A.2. 1H NMR spectrum of C6-OK [400 MHz, (CD3)2SO] 
 
A.3.4.The (5Z,5'Z)-5,5'-(((butane-1,4-diylbis(oxy))bis(6-nitro-3,1-phenylene))bis(methanylylid 
ene))bis(2-thioxothiazolidin-4-one) (C6-n2m) 
The C6-OK (471 mg, 1.47 mmol) was dissolved in dried DMF (5 mL) and stirred in the flask. Then 
1,4-dibromobutane (58.5 L, 0.49 mmol) was added drop-wise. The reaction mixture was refluxed at 
80 °C under the N2 condition for 6 h. After the reaction, the mixture was extracted EtOAc/water. The 
organic layer was collected, washed with brine, dried with MgSO4, filtered and concentrated. The 
crude was purified by column chromatography (SiO2, 1:1 hexanes/EtOAc, Rf = 0.4). The final product 
(pale yellow powder) was obtained. (80 mg, 1.5 mmol, 27% yield). 1H NMR (400 MHz, (CD3)2SO /  
(ppm): 11.34 (2H, s), 8.14 (2H, d, J = 9.26 Hz), 8.05, (2H, s), 7.00 (4H, m), 4.04 (4 H, s), 1.72 (4H, s). 
13C NMR (100 MHz, (CD3)2SO /  (ppm): 194.3, 166.7, 163.3, 139.8, 132.3, 130.7, 129.2, 127.2, 
1177, 115.7, 44.4, 24.2. ESI-MS Calcd for C24H17N4O8S4 [M-H]-, 617.994; found 617.161. 
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Figure A.3. 1H NMR spectrum of C6-n2m [400 MHz, (CD3)2SO] 
 
 
 
 
Figure A.4. 13C NMR spectrum of C6-OK [100 MHz, (CD3)2SO] 
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A.3.5. 5-((Z)-5-hydroxy-2-nitrobenzylidene)-3-(10-(4-nitro-3-((Z)-(4-oxo-2-thioxothiazolidin-5-
ylidene)methyl)phenoxy)decyl)-2-thioxothiazolidin-4-one (C6-n4m’) 
The C6-OK (320 mg, 1.07 mmol) was dissolved in dried DMF (5 mL) and stirred in the flask. Then 
1,10-dibromodecane (89.1 L, 0.43 mmol) was added drop-wise. The reaction mixture was refluxed 
at 80 °C under the N2 condition for 3 h. After the reaction, the mixture was extracted EtOAc/water. 
The organic layer was collected, washed with brine, dried with MgSO4, filtered and concentrated. The 
crude was purified by column chromatography (SiO2, 1:1 hexanes/EtOAc, Rf = 0.24). The final 
product (yellow powder) was obtained. (80 mg, 1.5 mmol, 27% yield). 1H NMR (400 MHz, (CD3)2SO 
/  (ppm): 11.34 (2H, s), 8.14 (4H, m), 8.07 (1H, s), 8.05 (1H, s), 6.99 (4H, m), 3.99 (4H, s), 1.62 (4H, 
s), 1.27 (12H, m). 13C NMR (100 MHz, (CD3)2SO /  (ppm): 194.2, 193.8, 178.2, 166.6, 163.7, 139.6, 
133.6, 133.2, 132.3, 131.1, 130.8, 129.2, 129.0, 117.8, 117.6, 116.0, 115.8, 44.8, 33.6, 29.1, 28.9, 28.8, 
28.3, 26.6, 26.5. ESI-MS Calcd for C30H29N4O8S4 [M-H]-, 701.087; found 701.359. 
 
 
Figure A.5. 1H NMR spectrum of C6-n4m’ [400 MHz, (CD3)2SO]  
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Figure A.6. 13C NMR spectrum of C6-n4m’ [100 MHz, (CD3)2SO] 
 
A.4. Conclusion 
The FosB, one of transcription factor, mediates endogenous resilience or handling mechanisms of 
stress. Overproduced FosB, however, is involved in drug addiction and diyskinesia. To inhibit the 
elevated level of FosB, designed inhibitor (C6) was developed by connection with linker. Newly 
synthesized compounds (C6-n2m and C6-n4m) are expected to show the lower IC50 value than C6 
analogue. The binding position of FosB with protein also could be predicted by length of linker. This 
work might be helpful for future work to develop the FosB inhibitor. 
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